<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Malar J</journal-id><journal-title>Malaria Journal</journal-title><issn pub-type="epub">1475-2875</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16704735</article-id><article-id pub-id-type="pmc">1475595</article-id><article-id pub-id-type="publisher-id">1475-2875-5-43</article-id><article-id pub-id-type="doi">10.1186/1475-2875-5-43</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Artemether-lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: randomized controlled trial</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Meremikwu</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mmeremiku@yahoo.co.uk</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Alaribe</surname><given-names>Ambrose</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>anyanwualaribe@yahoo.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Ejemot</surname><given-names>Regina</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>idulove@yahoo.com</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Oyo-Ita</surname><given-names>Angela</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Oyo_ita@yahoo.com</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Ekenjoku</surname><given-names>John</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>john_azubuike@yahoo.com</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Nwachukwu</surname><given-names>Chukwuemeka</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>dremeka31@yahoo.com</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Ordu</surname><given-names>Donald</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>donordu@yahoo.com</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Ezedinachi</surname><given-names>Emmanuel</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>eezedinachi@yahoo.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Calabar Institute of Tropical Disease Research &amp; Prevention, GPO Box 1211, Calabar, Nigeria</aff><aff id="I2"><label>2</label>Federal Ministry of Health, Abuja, Nigeria</aff><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>16</day><month>5</month><year>2006</year></pub-date><volume>5</volume><fpage>43</fpage><lpage>43</lpage><ext-link ext-link-type="uri" xlink:href="http://www.malariajournal.com/content/5/1/43"></ext-link><history><date date-type="received"><day>19</day><month>9</month><year>2005</year></date><date date-type="accepted"><day>16</day><month>5</month><year>2006</year></date></history><permissions><copyright-statement>Copyright © 2006 Meremikwu et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Meremikwu et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="3930" xml_f="3940" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="3951" xml_f="4091" txt_i="22" txt_f="162">The therapeutic efficacy of artesunate plus amodiaquine and artemether/lumefantrine were assessed in an area of Nigeria with high levels of </offsets><italic><offsets xml_i="4099" xml_f="4121" txt_i="162" txt_f="184">Plasmodium falciparum </offsets></italic><offsets xml_i="4130" xml_f="4187" txt_i="184" txt_f="241">resistance to chloroquine and sulphadoxine-pyrimethamine.</offsets></p></sec><sec><title><offsets xml_i="4209" xml_f="4221" txt_i="243" txt_f="255">Participants</offsets></title><p><offsets xml_i="4232" xml_f="4280" txt_i="256" txt_f="304">Children aged 6 to 59 months with uncomplicated </offsets><italic><offsets xml_i="4288" xml_f="4302" txt_i="304" txt_f="318">P. falciparum </offsets></italic><offsets xml_i="4311" xml_f="4419" txt_i="318" txt_f="426">infection and parasite density 1,000 to 200,000 parasites/μL enrolled following informed consent by parents.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="4460" xml_f="4467" txt_i="428" txt_f="435">Methods</offsets></title><p><offsets xml_i="4478" xml_f="4824" txt_i="436" txt_f="782">Eligible children were randomly assigned to receive either a 3-day course of artesunate (4 mg/kg) plus amodiaquine (10 mg/kg) or 6-dose course of artemether/lumefantrine (20/120 mg tablets) over three days. Patients were followed up with clinical and laboratory assessments until day 14 using standard WHO in-vivo antimalarial drug test protocol.</offsets></p></sec><sec><title><offsets xml_i="4846" xml_f="4853" txt_i="784" txt_f="791">Results</offsets></title><p><offsets xml_i="4864" xml_f="5516" txt_i="792" txt_f="1444">A total 119 eligible children were enrolled but 111 completed the study. Adequate clinical and parasitological response (ACPR) was 47 (87.0%) and 47 (82.5%) for artemether-lumefantrine (AL) and artesunate+amodiaquine (AAMQ) respectively (OR 0.7, 95% confidence interval 0.22 to 2.22). Early treatment failure (ETF) occurred in one participant (1.8%) treated with AAQ but in none of those with AL. Two (3.7%) patients in the AL group and none in the AAQ group had late clinical failure. Late parasitological failure was observed in 9 (15.8) and 5 (9.3%) of patients treated with AAQ and AL respectively. None of participants had a serious adverse event.</offsets></p></sec><sec><title><offsets xml_i="5538" xml_f="5548" txt_i="1446" txt_f="1456">Conclusion</offsets></title><p><offsets xml_i="5559" xml_f="5715" txt_i="1457" txt_f="1613">Artemether-lumenfantrine and artesunate plus amodiaquine have high and comparable cure rates and tolerability among under-five children in Calabar, Nigeria.</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="5777" xml_f="5787" txt_i="1622" txt_f="1632">Background</offsets></title><p><offsets xml_i="5798" xml_f="5983" txt_i="1633" txt_f="1818">Malaria accounts for more than one million deaths of mostly African children yearly. Early detection and prompt treatment is a key component of the global strategy for malaria control [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="6014" xml_f="6015" txt_i="1818" txt_f="1819">1</offsets></xref><offsets xml_i="6022" xml_f="6040" txt_i="1819" txt_f="1837">]. Across Africa, </offsets><italic><offsets xml_i="6048" xml_f="6070" txt_i="1837" txt_f="1859">Plasmodium falciparum </offsets></italic><offsets xml_i="6079" xml_f="6266" txt_i="1859" txt_f="2046">resistance to common affordable antimalarial drugs, chloroquine and sulphadoxine-pyrimethamine has reached very high levels, and noticably hampered malaria control efforts in the region [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="6297" xml_f="6298" txt_i="2046" txt_f="2047">2</offsets></xref><offsets xml_i="6305" xml_f="6588" txt_i="2047" txt_f="2330">]. In Nigeria, chloroquine and sulphadoxine-pyrimethamine have been the first and second line anti-malaria drugs respectively but evidence from local research spanning a period of two decades show that the therapeutic efficacy of these two drugs have deteriorated due to high levels </offsets><italic><offsets xml_i="6596" xml_f="6613" txt_i="2330" txt_f="2347">of P. falciparum </offsets></italic><offsets xml_i="6622" xml_f="6662" txt_i="2347" txt_f="2387">resistance in all parts of the country [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="6693" xml_f="6694" txt_i="2387" txt_f="2388">3</offsets></xref><offsets xml_i="6701" xml_f="6702" txt_i="2388" txt_f="2389">-</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="6733" xml_f="6734" txt_i="2389" txt_f="2390">5</offsets></xref><offsets xml_i="6741" xml_f="6743" txt_i="2390" txt_f="2392">].</offsets></p><p><offsets xml_i="6750" xml_f="6897" txt_i="2393" txt_f="2540">The World Health Organization recommends that combination treatment rather than monotherapy should be used in areas where multi-drug resistance to </offsets><italic><offsets xml_i="6905" xml_f="6919" txt_i="2540" txt_f="2554">P. falciparum </offsets></italic><offsets xml_i="6928" xml_f="6942" txt_i="2554" txt_f="2568">is a problem [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="6973" xml_f="6974" txt_i="2568" txt_f="2569">6</offsets></xref><offsets xml_i="6981" xml_f="7156" txt_i="2569" txt_f="2744">]. Combination drugs act at different sites or have different mechanisms of action, achieve better cure rates and are more likely to delay development of parasite resistance [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="7187" xml_f="7188" txt_i="2744" txt_f="2745">7</offsets></xref><offsets xml_i="7195" xml_f="7196" txt_i="2745" txt_f="2746">,</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="7227" xml_f="7228" txt_i="2746" txt_f="2747">8</offsets></xref><offsets xml_i="7235" xml_f="7651" txt_i="2747" txt_f="3163">]. Artemisinin-based combination treatments (ACTs) are preferred because artemisinin compounds have rapid parasite and fever clearance effects and also reduce gametocyte rate with the potential to reduce transmission. Artemisinin derivatives have short half life but the component combination drug, with a longer duration of action, makes up for this by providing sustained activity to eliminate remaining parasites[</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="7682" xml_f="7683" txt_i="3163" txt_f="3164">7</offsets></xref><offsets xml_i="7690" xml_f="7692" txt_i="3164" txt_f="3166">].</offsets></p><p><offsets xml_i="7699" xml_f="8031" txt_i="3167" txt_f="3499">The artemisinin-based combination treatment regimens are more expensive than each drug used singly, but their advantages over monotherapy far outweigh the cost. Artemisinin-based combination treatments are recommended for use as first-line treatment for uncomplicated malaria, even in resource-poor areas where multi-drug resistant </offsets><italic><offsets xml_i="8039" xml_f="8053" txt_i="3499" txt_f="3513">P. falciparum </offsets></italic><offsets xml_i="8062" xml_f="8086" txt_i="3513" txt_f="3537">infection is a problem [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="8117" xml_f="8118" txt_i="3537" txt_f="3538">6</offsets></xref><offsets xml_i="8125" xml_f="8224" txt_i="3538" txt_f="3637">]. ACTs have been used for a long time as first-line treatment in some South-East Asian countries [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="8255" xml_f="8256" txt_i="3637" txt_f="3638">9</offsets></xref><offsets xml_i="8263" xml_f="8264" txt_i="3638" txt_f="3639">,</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="8296" xml_f="8298" txt_i="3639" txt_f="3641">10</offsets></xref><offsets xml_i="8305" xml_f="8307" txt_i="3641" txt_f="3643">].</offsets></p><p><offsets xml_i="8314" xml_f="8598" txt_i="3644" txt_f="3928">The options under consideration in Nigeria for ACTs are amodiaquine with artesunate, or artemether-lumefantrine. Artemether-lumefantrine has reportedly high cure rates in observational studies, but controlled trials comparing it against other artemisinin containing regimens are few [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="8630" xml_f="8632" txt_i="3928" txt_f="3930">11</offsets></xref><offsets xml_i="8639" xml_f="9089" txt_i="3930" txt_f="4380">]. It has an advantage that the component drugs are coformulated in the same tablet but it is expensive, even at discounted rates, and requires patients to take six doses. Amodiaquine plus artesunate is less expensive, but not co-formulated, and therefore more likely to be misused as monotherapy. It is believed that cure rates of this combination regimen may be lower than with artemether-lumefantrine because of parasite resistance to amodiaquine.</offsets></p><p><offsets xml_i="9096" xml_f="9268" txt_i="4381" txt_f="4553">The Nigerian government supported randomized controlled trials in the six geopolitical zones of the country to assess the clinical efficacy and parasitological response of </offsets><italic><offsets xml_i="9276" xml_f="9290" txt_i="4553" txt_f="4567">P. falciparum </offsets></italic><offsets xml_i="9299" xml_f="9553" txt_i="4567" txt_f="4821">to combinations of artemether/lumefantrine and artesunate plus amodiaquine in treating uncomplicated childhood malaria. This paper describes one of these trials, conducted in the far-south geo-political zone within the Niger Delta region of the country. </offsets><italic><offsets xml_i="9561" xml_f="9575" txt_i="4821" txt_f="4835">P. falciparum </offsets></italic><offsets xml_i="9584" xml_f="9753" txt_i="4835" txt_f="5004">resistance to chloroquine was first documented in this region in 1987 and the current rate of resistance to chloroquine and sulphadoxine-pyrimethamine (SP) exceeds 80% [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="9784" xml_f="9785" txt_i="5004" txt_f="5005">3</offsets></xref><offsets xml_i="9792" xml_f="9793" txt_i="5005" txt_f="5006">,</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="9825" xml_f="9827" txt_i="5006" txt_f="5008">12</offsets></xref><offsets xml_i="9834" xml_f="9836" txt_i="5008" txt_f="5010">].</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="9877" xml_f="9884" txt_i="5012" txt_f="5019">Methods</offsets></title><sec><title><offsets xml_i="9904" xml_f="9929" txt_i="5020" txt_f="5045">Study area and population</offsets></title><p><offsets xml_i="9940" xml_f="10377" txt_i="5046" txt_f="5483">This study was conducted in Ikot Ansa a rural community within the Calabar Municipal Local Council area of Cross River State, Nigeria. The area has a projected population of 222,100, with 44,420 being under five years of age. This area lies within the tropical rainforest belt of southeastern Nigeria. The annual rainfall is 2,000–3,000 mm, within the rainy season lasting from April to October. There are two predominant ethnic groups, </offsets><italic><offsets xml_i="10385" xml_f="10391" txt_i="5483" txt_f="5489">Efiks </offsets></italic><offsets xml_i="10400" xml_f="10404" txt_i="5489" txt_f="5493">and </offsets><italic><offsets xml_i="10412" xml_f="10419" txt_i="5493" txt_f="5500">Ejagham</offsets></italic><offsets xml_i="10428" xml_f="10721" txt_i="5500" txt_f="5793">. The people's main occupations are subsistence farming, fishing and logging. Malaria is holoendemic in the study area with high and perennial transmission, especially in the rainy season (from April to November). The study was conducted in the months of September, October and November, 2004.</offsets></p></sec><sec><title><offsets xml_i="10743" xml_f="10760" txt_i="5795" txt_f="5812">Patient enrolment</offsets></title><p><offsets xml_i="10771" xml_f="11377" txt_i="5813" txt_f="6416">Children were enrolled if they had uncomplicated malaria, and fulfilled the following inclusion criteria: residence in study area, age 6–59 months, axillary temperature ≤37.5°C and parasite density of 1,000–200,000 asexual parasites/μl of blood, and informed consent by parents/guardian. Children with packed cell volume (PCV) &lt;15%, severe malnutrition, other signs of severe malaria or illness including any "danger sign" (viz. inability to drink or breastfeed, vomiting everything, recent history of convulsion, lethargy or unconsciousness, inability to sit or stand up, were excluded from the study [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="11409" xml_f="11411" txt_i="6416" txt_f="6418">12</offsets></xref><offsets xml_i="11418" xml_f="11420" txt_i="6418" txt_f="6420">].</offsets></p><p><offsets xml_i="11427" xml_f="11636" txt_i="6421" txt_f="6630">Ethical approval was given by the University of Calabar Teaching Hospital Ethical Committee. A written informed consent was obtained from each parent/legal guardian of eligible participants prior to enrolment.</offsets></p></sec><sec><title><offsets xml_i="11658" xml_f="11671" txt_i="6632" txt_f="6645">Randomization</offsets></title><p><offsets xml_i="11682" xml_f="12480" txt_i="6646" txt_f="7444">Participants were randomized by simple random sampling technique (drawing lots) in blocks of ten (10) to receive either artemether-lumefantrine (AL) or artesunate+amodiaquine. Allocation sequence was concealed in opaque, sealed and serially numbered envelopes. Study treatment was started on the day of randomization (day zero) and completed on day two, while follow-up continued for 14 days. Clinical examination plus body weight and height were recorded on day zero. Follow-up visits were scheduled on days 1, 2, 3, 7 and 14. On each visit, clinical examination including axillary temperature and thick blood film specimen obtained to screen for presence of malaria parasites and density was assessed by light microscopy. Packed cell volume (PCV) was estimated on day zero and repeated on day 14.</offsets></p></sec><sec><title><offsets xml_i="12502" xml_f="12515" txt_i="7446" txt_f="7459">Interventions</offsets></title><p><offsets xml_i="12526" xml_f="13385" txt_i="7460" txt_f="8319">Artesunate and amodiaquine were given orally at 4 mg/kg and 10 mg/kg body weight respectively, once daily on days 0, 1 and 2 with amodiaquine reduced to 5 mg/kg on day 2. Artemether/lumefantrine was given as 20/120 mg tablets. Participants weighing 5–14 kg received one tablet (20/120 mg), two tablets (40/240 mg) for body weight 1524 kg and three tablets for those weighing 25 – 35 kg. Each participant had a total of six doses of AL, with each dose at 12-hourly intervals for 3 days. Treatment was directly supervised by the research nurse and patients observed for 30 minutes. Drugs were re-administered to those who vomited within this period. Tepid sponging, exposure and administration of paracetamol at 15 mg/kg body weight were used to reduce high fever. Participants that did not return on schedule for follow-up were visited at home on the same day.</offsets></p></sec><sec><title><offsets xml_i="13407" xml_f="13431" txt_i="8321" txt_f="8345">Laboratory investigation</offsets></title><p><offsets xml_i="13442" xml_f="13592" txt_i="8346" txt_f="8496">Thick and thin blood smears were prepared and stained in 3% Giemsa solution for 30 minutes. The smears were read to 100 fields with quantification of </offsets><italic><offsets xml_i="13600" xml_f="13614" txt_i="8496" txt_f="8510">P. falciparum </offsets></italic><offsets xml_i="13623" xml_f="13730" txt_i="8510" txt_f="8617">asexual parasitaemia on the thick smear. Parasites were enumerated using thick film as described by Shute [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="13762" xml_f="13764" txt_i="8617" txt_f="8619">14</offsets></xref><offsets xml_i="13771" xml_f="14077" txt_i="8619" txt_f="8925">]. The parasite density (per μl of blood) was calculated, assuming a normal leucocyte level of 8,000/μl. The thin film was used to speciate the parasites. Packed Cell Volume (PCV) was measured on days 0 and 14 with sample collected in a heparinized capillary tube and centrifuged for 5 minutes at 10,000 G.</offsets></p></sec><sec><title><offsets xml_i="14099" xml_f="14107" txt_i="8927" txt_f="8935">Analysis</offsets></title><p><offsets xml_i="14118" xml_f="14390" txt_i="8936" txt_f="9208">Data generated were recorded in a log book, and individual patients case record files. Data were entered and analyzed with EPI-Info version 6.4. Data were also exported to SPSS version 11.0 for further analysis. Differences between groups were assessed using chi-square (X</offsets><sup><offsets xml_i="14395" xml_f="14396" txt_i="9208" txt_f="9209">2</offsets></sup><offsets xml_i="14402" xml_f="14559" txt_i="9209" txt_f="9366">), 't' test for continuous normally distributed variables and nonparametric Kruskal-Wallis was used to compare continuous not normally distributed variables.</offsets></p><p><offsets xml_i="14566" xml_f="14743" txt_i="9367" txt_f="9544">Therapeutic efficacy was determined on day 14 or earlier by assessing both clinical and parasitological response based on the WHO guidelines for assessing therapeutic efficacy [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="14775" xml_f="14777" txt_i="9544" txt_f="9546">15</offsets></xref><offsets xml_i="14784" xml_f="14861" txt_i="9546" txt_f="9623">]. The classification of treatment based on this protocol is shown on Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="14891" xml_f="14892" txt_i="9623" txt_f="9624">1</offsets></xref><offsets xml_i="14899" xml_f="14900" txt_i="9624" txt_f="9625">.</offsets></p><fig position="float" id="F1"><label><offsets xml_i="14941" xml_f="14949" txt_i="9626" txt_f="9634">Figure 1</offsets></label><caption><p><offsets xml_i="14969" xml_f="15013" txt_i="9634" txt_f="9678">Classification of malaria treatment outcome.</offsets></p></caption><graphic xlink:href="1475-2875-5-43-1"></graphic></fig></sec></sec><sec><title><offsets xml_i="15106" xml_f="15113" txt_i="9681" txt_f="9688">Results</offsets></title><sec><title><offsets xml_i="15133" xml_f="15141" txt_i="9689" txt_f="9697">Patients</offsets></title><p><offsets xml_i="15152" xml_f="15253" txt_i="9698" txt_f="9799">A total of 594 children were screened and 119 eligible ones were enrolled. The trial profile (Figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="15283" xml_f="15284" txt_i="9799" txt_f="9800">2</offsets></xref><offsets xml_i="15291" xml_f="15731" txt_i="9800" txt_f="10240">) shows the pattern and reasons for exclusion and losses to follow up. A total of six (10.0%) and two (3.4%) were respectively lost to follow-up in the artesunate/lumefandtrine (AL) and the artesunate/amodiaquine (AAMQ) groups. The AL arm had 60 participants, while the AAMQ arm had 59. A total of 54 participants who received AL and 57 who received AAMQ completed the trial, and had adequate data for the analysis of the end-points. Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="15763" xml_f="15764" txt_i="10240" txt_f="10241">1</offsets></xref><offsets xml_i="15771" xml_f="16107" txt_i="10241" txt_f="10577"> shows the baseline characteristics of the eligible participants. The two treatment groups were comparable in all characteristics. Data on previous antimalarial drug-use pattern shows that 11 (9.2%) of the enrolled participants had used antimalarial drugs in the past two weeks. The majority of these (8/11; 72.7%) had used chloroquine.</offsets></p><fig position="float" id="F2"><label><offsets xml_i="16148" xml_f="16156" txt_i="10578" txt_f="10586">Figure 2</offsets></label><caption><p><offsets xml_i="16176" xml_f="16190" txt_i="10586" txt_f="10600">Trial Profile.</offsets></p></caption><graphic xlink:href="1475-2875-5-43-2"></graphic></fig><table-wrap position="float" id="T1"><label><offsets xml_i="16303" xml_f="16310" txt_i="10601" txt_f="10608">Table 1</offsets></label><caption><p><offsets xml_i="16330" xml_f="16370" txt_i="10608" txt_f="10648">Baseline characteristics of participants</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><offsets xml_i="16449" xml_f="16474" txt_i="10649" txt_f="10674">Characteristics Mean (SD)</offsets></td><td align="left"><offsets xml_i="16496" xml_f="16529" txt_i="10675" txt_f="10708">Artesunate + amodiaquine (N = 59)</offsets></td><td align="left"><offsets xml_i="16551" xml_f="16583" txt_i="10709" txt_f="10741">Artemether-lumefantrine (N = 60)</offsets></td><td align="left"><offsets xml_i="16605" xml_f="16621" txt_i="10742" txt_f="10758">Test statistics*</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="16667" xml_f="16680" txt_i="10759" txt_f="10772">Age in months</offsets></td><td align="left"><offsets xml_i="16702" xml_f="16713" txt_i="10773" txt_f="10784">29.1 (17.1)</offsets></td><td align="left"><offsets xml_i="16735" xml_f="16745" txt_i="10785" txt_f="10795">28.2(16.2)</offsets></td><td align="left"><offsets xml_i="16767" xml_f="16772" txt_i="10796" txt_f="10801">0.43†</offsets></td></tr><tr><td align="left"><offsets xml_i="16803" xml_f="16816" txt_i="10802" txt_f="10815">Sex (Male) ‡:</offsets></td><td align="left"><offsets xml_i="16838" xml_f="16847" txt_i="10816" txt_f="10825">28 (47.5)</offsets></td><td align="left"><offsets xml_i="16869" xml_f="16878" txt_i="10826" txt_f="10835">33 (55.0)</offsets></td><td align="left"><offsets xml_i="16900" xml_f="16905" txt_i="10836" txt_f="10841">0.68‡</offsets></td></tr><tr><td align="left"><offsets xml_i="16936" xml_f="16948" txt_i="10842" txt_f="10854">Weight in Kg</offsets></td><td align="left"><offsets xml_i="16970" xml_f="16979" txt_i="10855" txt_f="10864">12.4(3.8)</offsets></td><td align="left"><offsets xml_i="17001" xml_f="17010" txt_i="10865" txt_f="10874">12.3(3.0)</offsets></td><td align="left"><offsets xml_i="17032" xml_f="17037" txt_i="10875" txt_f="10880">0.59†</offsets></td></tr><tr><td align="left"><offsets xml_i="17068" xml_f="17085" txt_i="10881" txt_f="10898">Height in cm (SD)</offsets></td><td align="left"><offsets xml_i="17107" xml_f="17117" txt_i="10899" txt_f="10909">86.7(13.7)</offsets></td><td align="left"><offsets xml_i="17139" xml_f="17149" txt_i="10910" txt_f="10920">85.6(12.7)</offsets></td><td align="left"><offsets xml_i="17171" xml_f="17176" txt_i="10921" txt_f="10926">0.64†</offsets></td></tr><tr><td align="left"><offsets xml_i="17207" xml_f="17231" txt_i="10927" txt_f="10951">Packed cell volume Day-0</offsets></td><td align="left"><offsets xml_i="17253" xml_f="17263" txt_i="10952" txt_f="10962">28.8 (4.9)</offsets></td><td align="left"><offsets xml_i="17285" xml_f="17295" txt_i="10963" txt_f="10973">28.9 (4.5)</offsets></td><td align="left"><offsets xml_i="17317" xml_f="17322" txt_i="10974" txt_f="10979">0.32†</offsets></td></tr><tr><td align="left"><offsets xml_i="17353" xml_f="17378" txt_i="10980" txt_f="11005">Packed cell volume Day-14</offsets></td><td align="left"><offsets xml_i="17400" xml_f="17410" txt_i="11006" txt_f="11016">33.3 (3.6)</offsets></td><td align="left"><offsets xml_i="17432" xml_f="17442" txt_i="11017" txt_f="11027">33.6 (4.0)</offsets></td><td align="left"><offsets xml_i="17464" xml_f="17469" txt_i="11028" txt_f="11033">0.43†</offsets></td></tr><tr><td align="left"><offsets xml_i="17500" xml_f="17525" txt_i="11034" txt_f="11059">Axillary temperature (°C)</offsets></td><td align="left"><offsets xml_i="17547" xml_f="17558" txt_i="11060" txt_f="11071">38.5 (0.96)</offsets></td><td align="left"><offsets xml_i="17580" xml_f="17590" txt_i="11072" txt_f="11082">38.6(0.81)</offsets></td><td align="left"><offsets xml_i="17612" xml_f="17617" txt_i="11083" txt_f="11088">0.87†</offsets></td></tr><tr><td align="left"><offsets xml_i="17648" xml_f="17692" txt_i="11089" txt_f="11133">Geometric mean parasite density in μL(range)</offsets></td><td align="left"><offsets xml_i="17714" xml_f="17739" txt_i="11134" txt_f="11159">7972.0 (1,000 to 258,824)</offsets></td><td align="left"><offsets xml_i="17761" xml_f="17786" txt_i="11160" txt_f="11185">7972.3 (1,011 to 318,769)</offsets></td><td align="left"><offsets xml_i="17808" xml_f="17813" txt_i="11186" txt_f="11191">0.73§</offsets></td></tr></tbody></table><table-wrap-foot><p><sup><offsets xml_i="17864" xml_f="17865" txt_i="11192" txt_f="11193">‡</offsets></sup><offsets xml_i="17871" xml_f="17907" txt_i="11193" txt_f="11229">Frequency (%) and Chi-squared test; </offsets><sup><offsets xml_i="17912" xml_f="17913" txt_i="11229" txt_f="11230">†</offsets></sup><offsets xml_i="17919" xml_f="17927" txt_i="11230" txt_f="11238">t-test; </offsets><sup><offsets xml_i="17932" xml_f="17933" txt_i="11238" txt_f="11239">§</offsets></sup><offsets xml_i="17939" xml_f="17961" txt_i="11239" txt_f="11261">Kruskal-Wallis H test;</offsets></p><p><offsets xml_i="17968" xml_f="18052" txt_i="11262" txt_f="11346">*All tests show that both study groups were not statistically significant different.</offsets></p></table-wrap-foot></table-wrap></sec><sec><title><offsets xml_i="18105" xml_f="18113" txt_i="11348" txt_f="11356">Outcomes</offsets></title><p><offsets xml_i="18124" xml_f="18130" txt_i="11357" txt_f="11363">Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="18162" xml_f="18163" txt_i="11363" txt_f="11364">2</offsets></xref><offsets xml_i="18170" xml_f="18665" txt_i="11364" txt_f="11859"> shows the results of the 14-day therapeutic efficacy of the drugs. The number of evaluable participants with adequate clinical and parasitological response (ACPR) were 47 (87.0%) and 47 (82.5%) for AL and AAMQ, respectively. The difference in the cures rates of the two regimens was not statistically significant (Odds ratio 0.7, 95% confidence interval 0.22 to 2.22). Early treatment failure (ETF) was observed in one participant (1.8%) that received AAMQ but in none of those treated with AL.</offsets></p><table-wrap position="float" id="T2"><label><offsets xml_i="18713" xml_f="18720" txt_i="11860" txt_f="11867">Table 2</offsets></label><caption><p><offsets xml_i="18740" xml_f="18788" txt_i="11867" txt_f="11915">Therapeutic efficacy of artemether-lumefantrine </offsets><italic><offsets xml_i="18796" xml_f="18803" txt_i="11915" txt_f="11922">versus </offsets></italic><offsets xml_i="18812" xml_f="18854" txt_i="11922" txt_f="11964">artesunate+amodiaquine in Calabar Nigeria.</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><offsets xml_i="18933" xml_f="18964" txt_i="11965" txt_f="11996">Indicators of treatment outcome</offsets></td><td align="center" colspan="2"><offsets xml_i="19000" xml_f="19026" txt_i="11997" txt_f="12023">Number (%) of participants</offsets></td></tr><tr><td></td><td colspan="2"><hr></hr></td></tr><tr><td></td><td align="left"><offsets xml_i="19114" xml_f="19147" txt_i="12027" txt_f="12060">Artesunate + Amodiaquine (n = 57)</offsets></td><td align="left"><offsets xml_i="19169" xml_f="19201" txt_i="12061" txt_f="12093">Artemether-lumefantrine (n = 54)</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="19247" xml_f="19300" txt_i="12094" txt_f="12147">Adequate Clinical and parasitological response (ACPR)</offsets></td><td align="left"><offsets xml_i="19322" xml_f="19331" txt_i="12148" txt_f="12157">47 (82.5)</offsets></td><td align="left"><offsets xml_i="19353" xml_f="19362" txt_i="12158" txt_f="12167">47 (87.0)</offsets></td></tr><tr><td align="left"><offsets xml_i="19393" xml_f="19422" txt_i="12168" txt_f="12197">Early treatment failure (ETF)</offsets></td><td align="left"><offsets xml_i="19444" xml_f="19450" txt_i="12198" txt_f="12204">1(1.8)</offsets></td><td align="left"><offsets xml_i="19472" xml_f="19479" txt_i="12205" txt_f="12212">0 (0.0)</offsets></td></tr><tr><td align="left"><offsets xml_i="19510" xml_f="19537" txt_i="12213" txt_f="12240">Late clinical failure (LCF)</offsets></td><td align="left"><offsets xml_i="19559" xml_f="19566" txt_i="12241" txt_f="12248">0 (0.0)</offsets></td><td align="left"><offsets xml_i="19588" xml_f="19595" txt_i="12249" txt_f="12256">2 (3.7)</offsets></td></tr><tr><td align="left"><offsets xml_i="19626" xml_f="19660" txt_i="12257" txt_f="12291">Late parasitological failure (LPF)</offsets></td><td align="left"><offsets xml_i="19682" xml_f="19689" txt_i="12292" txt_f="12299">9(15.8)</offsets></td><td align="left"><offsets xml_i="19711" xml_f="19718" txt_i="12300" txt_f="12307">5 (9.3)</offsets></td></tr></tbody></table></table-wrap><p><offsets xml_i="19760" xml_f="19767" txt_i="12308" txt_f="12315">Figure </offsets><xref ref-type="fig" rid="F3"><offsets xml_i="19797" xml_f="19798" txt_i="12315" txt_f="12316">3</offsets></xref><offsets xml_i="19805" xml_f="20041" txt_i="12316" txt_f="12552"> shows that both treatment regimens had rapid and comparable fever clearance rates. One participant that received AAMQ had pains in the ear, which resolved before day 14. No other adverse events were observed in either treatment groups.</offsets></p><fig position="float" id="F3"><label><offsets xml_i="20082" xml_f="20090" txt_i="12553" txt_f="12561">Figure 3</offsets></label><caption><p><offsets xml_i="20110" xml_f="20186" txt_i="12561" txt_f="12634">Percentage of children with fever (temperature &gt; 37.4°C) during follow-up</offsets></p></caption><graphic xlink:href="1475-2875-5-43-3"></graphic></fig></sec></sec><sec><title><offsets xml_i="20279" xml_f="20289" txt_i="12637" txt_f="12647">Discussion</offsets></title><p><offsets xml_i="20300" xml_f="20452" txt_i="12648" txt_f="12800">The key goal of artemisinin-based combination treatment (ACT) is to enhance cure rates and delay development of parasite resistance to component drugs [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="20484" xml_f="20486" txt_i="12800" txt_f="12802">16</offsets></xref><offsets xml_i="20493" xml_f="20739" txt_i="12802" txt_f="13048">]. This study has shown rapid parasite and fever clearance in children treated with 6-dose regimen of artemether-lumefantrine (AL) and 3-day course of artesunate plus amodiaquine (AAMQ). This is characteristic of artemisinin combination therapy [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="20770" xml_f="20771" txt_i="13048" txt_f="13049">6</offsets></xref><offsets xml_i="20778" xml_f="21145" txt_i="13049" txt_f="13416">]. It was also demonstrated that these ACT regimens were tolerable among under-five children in this locality. The ACTs were not compared with existing first-line and second-line drugs for uncomplicated malaria (chloroquine or sulphadoxine-pyrimethamine,) because of very high treatment failures (in excess of 80%) recently reported for both drugs in the study area [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="21177" xml_f="21179" txt_i="13416" txt_f="13418">12</offsets></xref><offsets xml_i="21186" xml_f="21323" txt_i="13418" txt_f="13555">]. Administering such ineffective treatments to ill, under-five children could significantly increase the risk of poor treatment outcome.</offsets></p><p><offsets xml_i="21330" xml_f="21643" txt_i="13556" txt_f="13866">The cure rates obtained for a 6-dose regimen of AL and a 3-day course of AAMQ were high (&gt; 80%) but fell short of therapeutic efficacy levels reported in other areas. Day-14 cure rates for AAMQ were 91%, 93%, and 98% in Kenya, Senegal and Gabon, with lower day-28 cure rates of 68%, 82% and 85%, respectively [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="21675" xml_f="21677" txt_i="13866" txt_f="13868">17</offsets></xref><offsets xml_i="21684" xml_f="21793" txt_i="13868" txt_f="13977">]. Another report of 14-day in-vivo study of AAMQ in Mozambique showed a parasitological cure rate of 94.3% [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="21824" xml_f="21825" txt_i="13977" txt_f="13978">8</offsets></xref><offsets xml_i="21832" xml_f="21834" txt_i="13978" txt_f="13980">].</offsets></p><p><offsets xml_i="21841" xml_f="22048" txt_i="13981" txt_f="14188">The 14-day cure rate obtained for a 6-dose regimen of AL in the present study is comparable with those reported for 4-dose regimen in other trials, but lower than cure rates obtained in other 6-dose trials [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="22079" xml_f="22080" txt_i="14188" txt_f="14189">9</offsets></xref><offsets xml_i="22087" xml_f="22088" txt_i="14189" txt_f="14190">,</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="22120" xml_f="22122" txt_i="14190" txt_f="14192">11</offsets></xref><offsets xml_i="22129" xml_f="22245" txt_i="14192" txt_f="14308">]. A 42-day cure rate of 93.6% has been documented in a recent randomized controlled trial of 6-dose regimen of AL [</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="22277" xml_f="22279" txt_i="14308" txt_f="14310">18</offsets></xref><offsets xml_i="22286" xml_f="22288" txt_i="14310" txt_f="14312">].</offsets></p><p><offsets xml_i="22295" xml_f="22645" txt_i="14313" txt_f="14663">This study has demonstrated comparable therapeutic efficacy and tolerability for a 6 dose regimen of artemether-lumefantrine and a 3-day course of artesunate plus amodiaquine. This apparent lack of difference in effects may be because the study samples were small and lacked statistical power to detect significant difference at 95% confidence level.</offsets></p><p><offsets xml_i="22652" xml_f="22884" txt_i="14664" txt_f="14896">The short follow-up period of 14 days is another methodological limitation of this study. Recent observations have shown that treatment failures affecting artemisininbased combination treatment regimens tend to occur after 21 days [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="22916" xml_f="22918" txt_i="14896" txt_f="14898">19</offsets></xref><offsets xml_i="22925" xml_f="23151" txt_i="14898" txt_f="15124">]. The minimum follow-up period currently recommended this type of studies is 28 days. This trial started before the evidence that 14-day follow-up period is inadequate for in-vivo efficacy studies of ACTs became overwhelming.</offsets></p><p><offsets xml_i="23158" xml_f="23483" txt_i="15125" txt_f="15450">The Nigerian government has reviewed the malaria treatment policy, replacing chloroquine and sulphadoxine-pyrimethamine with artemisinin-based combination treatment (ACT) as the first-line treatment for uncomplicated malaria. This change in policy has been informed by evidence from local studies like the one reported here [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="23515" xml_f="23517" txt_i="15450" txt_f="15452">20</offsets></xref><offsets xml_i="23524" xml_f="23896" txt_i="15452" txt_f="15824">]. Larger effectiveness studies with higher statistical power than the present study will be needed to ascertain the effects of these drug combinations in this area. Prospective sentinel monitoring of the use and effectiveness of the new ACTs at strategic geographical locations in the country would provide reliable evidence for health planning and future policy reviews.</offsets></p></sec><sec><title><offsets xml_i="23918" xml_f="23940" txt_i="15826" txt_f="15848">Authors' contributions</offsets></title><p><offsets xml_i="23951" xml_f="24114" txt_i="15849" txt_f="16012">Martin Meremikwu, Emmanuel Ezedinachi and Donald Ordu developed the protocol and supervised the trial. All the authors contributed to the preparation of the paper.</offsets></p><fig position="float" id="F4"><label><offsets xml_i="24155" xml_f="24163" txt_i="16013" txt_f="16021">Figure 4</offsets></label><caption><p><offsets xml_i="24183" xml_f="24223" txt_i="16021" txt_f="16061">Parasite clearance pattern up to Day-14.</offsets></p></caption><graphic xlink:href="1475-2875-5-43-4"></graphic></fig></sec></body><back><ack><sec><title>Acknowledgements</title><p>This study was supported by the Federal Ministry of Health and the World Health Organization. We are grateful to Dr Iyam Ugot and Dr Henry Nsa (State Roll Back Malaria Project) for their support. The contribution of the following team members is acknowledged with thanks: Microscopists (Bam Ogar, Ewuosho, Ime Mkpang), nurses (Funmi Siyanbade, Mbang Bassey), clinician assistant (Elemi Iwasam), follow-up (Chima Nwaneri, Bassey Obeten, Asa Martins, Eyeh Ikang). Several other staff members of the Ikot Ansa Health Centre, State RBM project and Nigerian Army Eburutu Barracks Medical Centre (not listed here) and the Ikot Ansa Clan Council who helped in facilitating the study are gratefully acknowledged.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="book"><person-group person-group-type="author"><collab>WHO</collab></person-group><source>A global strategy for malaria control</source><year>1993</year><publisher-name>Geneva: World Health Organization</publisher-name></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bloland</surname><given-names>PB</given-names></name><name><surname>Ettling</surname><given-names>M</given-names></name></person-group><article-title>Making malaria treatment policy in the face of drug resistance</article-title><source>Ann Trop Med Parasitol</source><year>1999</year><volume>93</volume><fpage>5</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">10492667</pub-id><pub-id pub-id-type="doi">10.1080/00034989958753</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ezedinachi</surname><given-names>ENU</given-names></name><name><surname>Alaribe</surname><given-names>AA</given-names></name><name><surname>Meremikwu</surname><given-names>M</given-names></name><name><surname>Ejezie</surname><given-names>GC</given-names></name></person-group><article-title>New trends in chloroquine efficacy in the treatment of malaria</article-title><source>Central Afr J Med</source><year>1992</year><volume>38</volume><fpage>303</fpage><lpage>307</lpage></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Falade</surname><given-names>CO</given-names></name><name><surname>Salako</surname><given-names>LA</given-names></name><name><surname>Sowunmi</surname><given-names>A</given-names></name><name><surname>Oduola</surname><given-names>AMJ</given-names></name><name><surname>Larcier</surname><given-names>P</given-names></name></person-group><article-title>Comparative efficacy of halofantrine, chloroquine and sulphadoxine-pyrimethamine for treatment of acute uncomplicated malaria in Nigerian children</article-title><source>Trans R Soc Trop Med Hyg</source><year>1997</year><volume>91</volume><fpage>58</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">9093631</pub-id><pub-id pub-id-type="doi">10.1016/S0035-9203(97)90397-7</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ekanem</surname><given-names>OJ</given-names></name><name><surname>Ezedinachi</surname><given-names>ENU</given-names></name><name><surname>Molta</surname><given-names>NB</given-names></name><name><surname>Watila</surname><given-names>IM</given-names></name><name><surname>Chukwuani</surname><given-names>CM</given-names></name><name><surname>Meremikwu</surname><given-names>MM</given-names></name><name><surname>Akpede</surname><given-names>G</given-names></name><name><surname>Ojar</surname><given-names>EA</given-names></name></person-group><article-title>Treatment of malaria in North-Eastern and South-Eastern Nigeria: a population study of mefloquine, sulphadoxine, pyrimethamine combination (MSP) vs chloroquine</article-title><source>West Afr J Med</source><year>2000</year><volume>19</volume><fpage>293</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">11391844</pub-id></citation></ref><ref id="B6"><citation citation-type="book"><person-group person-group-type="author"><collab>WHO</collab></person-group><source>Anti-malarial drug combination therapy: Report of a WHO technical consultation</source><publisher-name>[Document WHO/CDS/RBM/2001.35] Geneva</publisher-name></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Olliaro</surname><given-names>PL</given-names></name></person-group><article-title>Strategies for prevention of antimalarial drug resistance: rationale for combination therapy for malaria</article-title><source>Parasitol Today</source><year>1996</year><volume>12</volume><fpage>399</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">15275291</pub-id><pub-id pub-id-type="doi">10.1016/0169-4758(96)10055-7</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abacassamo</surname><given-names>F</given-names></name><name><surname>Enosse</surname><given-names>S</given-names></name><name><surname>Aponte</surname><given-names>JJ</given-names></name><name><surname>Gomez-Olive</surname><given-names>FX</given-names></name><name><surname>Quinto</surname><given-names>L</given-names></name><name><surname>Mabunda</surname><given-names>S</given-names></name><name><surname>Barreto</surname><given-names>A</given-names></name><name><surname>Magnussen</surname><given-names>P</given-names></name><name><surname>Ronn</surname><given-names>AM</given-names></name><name><surname>Thompson</surname><given-names>R</given-names></name><name><surname>Alonso</surname><given-names>PL</given-names></name></person-group><article-title>Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria</article-title><source>Trop Med Int Health</source><year>2004</year><volume>9</volume><fpage>200</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">15040556</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-3156.2003.01182.x</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lefevre</surname><given-names>G</given-names></name><name><surname>Looareesuwam</surname><given-names>S</given-names></name><name><surname>Treepraertsuk</surname><given-names>S</given-names></name><name><surname>Krudsood</surname><given-names>S</given-names></name><name><surname>Silachamroon</surname><given-names>U</given-names></name><name><surname></surname><given-names>I</given-names></name><name><surname>Mull</surname><given-names>R</given-names></name><name><surname>Bakshi</surname><given-names>R</given-names></name></person-group><article-title>A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant <italic>Plasmodium falciparum </italic>malaria in Thailand</article-title><source>Am J Trop Med Hyg</source><year>2001</year><volume>64</volume><fpage>247</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">11463111</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mayxay</surname><given-names>M</given-names></name><name><surname>Khanthavong</surname><given-names>M</given-names></name><name><surname>Lindegardh</surname><given-names>N</given-names></name><name><surname>Keola</surname><given-names>S</given-names></name><name><surname>Barends</surname><given-names>M</given-names></name><name><surname>Pongvongsa</surname><given-names>T</given-names></name><name><surname>Yapom</surname><given-names>R</given-names></name><name><surname>Annerberg</surname><given-names>A</given-names></name><name><surname>Phompida</surname><given-names>S</given-names></name><name><surname>Phetsouvanh</surname><given-names>R</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Newton</surname><given-names>PN</given-names></name></person-group><article-title>Randomized comparison of chloroquine plus sulfadoxinepyrimethamine versus artesunate plus mefloquine versus artemetherlumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic</article-title><source>Clin Infect Dis</source><year>2004</year><volume>39</volume><fpage>1139</fpage><lpage>1147</lpage><pub-id pub-id-type="pmid">15486837</pub-id><pub-id pub-id-type="doi">10.1086/424512</pub-id></citation></ref><ref id="B11"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Omari</surname><given-names>AAA</given-names></name><name><surname>Preston</surname><given-names>C</given-names></name><name><surname>Garner</surname><given-names>P</given-names></name></person-group><article-title>Artemether-Lumefantrine for treating uncomplicated falciparium malaria (Cochrane review)</article-title><source>The Cochrane Library</source><year>2004</year></citation></ref><ref id="B12"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Meremikwu</surname><given-names>M</given-names></name><name><surname>Egbuna</surname><given-names>C</given-names></name><name><surname>Philip-Ephraim</surname><given-names>E</given-names></name><name><surname>Alaribe</surname><given-names>A</given-names></name><name><surname>Odok</surname><given-names>J</given-names></name><name><surname>Ewuosho</surname><given-names></given-names></name><name><surname>Bassey</surname><given-names>A</given-names></name><name><surname>Dioka</surname><given-names>P</given-names></name></person-group><article-title>Therapeutic efficacy test of chloroquine and sulfadoxine-pyrimethamine for uncomplicated malaria in preschool children in Akpabuyo, Cross River State Nigeria</article-title><source>A report submitted to the Federal Ministry of Health, Abuja</source><year>2002</year></citation></ref><ref id="B13"><citation citation-type="book"><person-group person-group-type="author"><collab>WHO</collab></person-group><source>Management of severe malaria A practical handbook</source><year>2000</year><publisher-name>Geneva: World Health Organization</publisher-name></citation></ref><ref id="B14"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Shute</surname><given-names>GT</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Wernsdorfer, McGregor L</surname></name></person-group><article-title>The microscopic diagnosis of malaria</article-title><source>Principle and practice of malariology</source><year>1988</year><publisher-name>Edinburgh: Churchhill Livingstone</publisher-name><fpage>781</fpage><lpage>814</lpage></citation></ref><ref id="B15"><citation citation-type="book"><person-group person-group-type="author"><collab>WHO</collab></person-group><source>Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparium malaria</source><publisher-name>WHO/HTM/RBM/2003.50. Geneva</publisher-name></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>NJ</given-names></name></person-group><article-title>Delaying antimalarial drug resistance with combination chemotherapy</article-title><source>Parasitologia</source><year>1999</year><volume>41</volume><fpage>301</fpage><lpage>308</lpage></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adjuik</surname><given-names>M</given-names></name><name><surname>Agnamey</surname><given-names>P</given-names></name><name><surname>Babiker</surname><given-names>A</given-names></name><name><surname>Borrmann</surname><given-names>S</given-names></name><name><surname>Brasseur</surname><given-names>P</given-names></name><name><surname>Cisse</surname><given-names>M</given-names></name><name><surname>Cobelens</surname><given-names>F</given-names></name><name><surname>Diallo</surname><given-names>S</given-names></name><name><surname>Faucher</surname><given-names>JF</given-names></name><name><surname>Garner</surname><given-names>P</given-names></name><name><surname>Gikunda</surname><given-names>S</given-names></name><name><surname>Kremsner</surname><given-names>PG</given-names></name><name><surname>Krishna</surname><given-names>S</given-names></name><name><surname>Lell</surname><given-names>B</given-names></name><name><surname>Loolpapit</surname><given-names>M</given-names></name><name><surname>Matsiegui</surname><given-names>PB</given-names></name><name><surname>Missinou</surname><given-names>MA</given-names></name><name><surname>Mwanza</surname><given-names>J</given-names></name><name><surname>Ntoumi</surname><given-names>F</given-names></name><name><surname>Olliaro</surname><given-names>P</given-names></name><name><surname>Osimbo</surname><given-names>P</given-names></name><name><surname>Rezbach</surname><given-names>P</given-names></name><name><surname>Some</surname><given-names>E</given-names></name><name><surname>Taylor</surname><given-names>WR</given-names></name></person-group><article-title>Amodiaquine-artesunate versus amodiaquine for uncomplicated <italic>Plasmodium falciparum </italic>malaria in African children: a randomised, multicentre trial</article-title><source>Lancet</source><year>2002</year><volume>359</volume><fpage>1365</fpage><lpage>1372</lpage><pub-id pub-id-type="pmid">11978332</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(02)08348-4</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stohrer</surname><given-names>JM</given-names></name><name><surname>Dittrich</surname><given-names>S</given-names></name><name><surname>Thongpaseuth</surname><given-names>V</given-names></name><name><surname>Vanisaveth</surname><given-names>V</given-names></name><name><surname>Phetsouvanh</surname><given-names>R</given-names></name><name><surname>Phompida</surname><given-names>S</given-names></name><name><surname>Monti</surname><given-names>F</given-names></name><name><surname>Christophel</surname><given-names>EM</given-names></name><name><surname>Lindegardh</surname><given-names>N</given-names></name><name><surname>Annerberg</surname><given-names>A</given-names></name><name><surname>Jelinek</surname><given-names>T</given-names></name></person-group><article-title>Therapeutic efficacy of artemether-lumefantrine and artesunatemefloquine for treatment of uncomplicated <italic>Plasmodium falciparum </italic>malaria in Luang Namtha Province, Lao People's Democratic Republic</article-title><source>Trop Med Int Health</source><year>2004</year><volume>9</volume><fpage>1175</fpage><lpage>1183</lpage><pub-id pub-id-type="pmid">15548313</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-3156.2004.01320.x</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ashley</surname><given-names>EA</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name></person-group><article-title>Artemisinin-based combinations</article-title><source>Curr Opin Infect Dis</source><year>2005</year><volume>18</volume><fpage>531</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">16258328</pub-id><pub-id pub-id-type="doi">10.1097/01.qco.0000186848.46417.6c</pub-id></citation></ref><ref id="B20"><citation citation-type="book"><person-group person-group-type="author"><collab>Federal Ministry of Health</collab></person-group><source>National malaria control programme 2004 Annual report</source><year>2005</year><publisher-name>Abuja: FMOH</publisher-name></citation></ref></ref-list></back></article>